Bone Cement Treatment Boosts Quality of Life for Patients With Metastatic Cancer
From October 27, 2025, patients in the Netherlands with spinal metastases or multiple myeloma can access bone cement injections.
Market Access
Brensocatib faces ICER spotlight with strong case for clinical and economic value
ICER pegs an ~$88K benchmark for brensocatib and spotlights evidence gaps shaping NCFB access.
Reimbursement Series: CMS and Europe Reimbursement Pathway Accelerates Innovation
In a transformative week for market access, the CMS and Europe reimbursement pathway expansion delivered several pivotal coverage and pricing decisions reshaping patient access across cardiovascular, hepatic, and oncology therapies. From CMS’s national determinations on breakthrough devices to European HTA approvals in rare disease and cancer, these developments underscore a growing transatlantic alignment between regulators … Read more
New Proposal Calls for Funeral Reimbursement to Boost U.S. Organ Donation
Funeral reimbursement could transform U.S. organ donation access and equity.
Evernorth Secures Breakthrough Pricing Shift in Drug Access
Evernorth’s pricing model overhaul transforms drug access and reimbursement dynamics.
Baird Medical Secures Pivotal Reimbursement Win for MWA
Successful reimbursement milestone strengthens device adoption and access strategy.
UK Government Unlocks Game-Changing Drug Pricing Strategy
UK braces as drug pricing shifts dramatically in market access landscape.
HAS Stroke Update Transforms Access on World Stroke Day
HAS strengthens stroke management for faster, equitable emergency care access.
Reimbursement Series: Anchors Affordable Breakthroughs – AIFA and TLV Expand European Coverage
Sweden expands reimbursement decisions driving biotech access and patient impact.
NICE Secures Breakthrough HTA Decision for Prostate Cancer
NICE issues breakthrough HTA decision on Bayer’s prostate cancer therapy.